Resources

Asahi Kasei Bioprocess America and GeminiBio enter strategic partnership to advance application of Inline Buffer Formulation and streamline biopharmaceutical manufacturing processes. The strategic partnership will establish a joint solution for the efficient creation of buffers created from concentrates delivered directly to manufacturing facilities, increasing productivity and speed to market. • Costs for biopharmaceutical production can be significantly reduced, positively affecting the accessibility of medication for patients globally. • This partnership will be a catalyst for innovation at both companies, driving new industry standards.

GeminiBio opens new cGMP bioprocess liquid manufacturing facility, expanding capabilities to better serve the biotechnology and cell & gene therapy markets

Gemini BioProducts Holding, Inc. (“GeminiBio” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, and BroadOak Capital Partners, a life science focused investment firm, announced today the appointment of Bryan Poltilove to the Board of Directors.

Gemini BioProducts Holding, Inc. (“GeminiBio” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, announced the appointment of Gopi Natarajan to the Board of Directors.

Southeast US-based Gene Therapy company scaling to clinical stage had been making required process liquids – lab scale – internally, but required an outsourcing partner to simplify the workflow with pre-made process liquids much larger than the internal lab could manage – and can scale to cGMP when needed.

US-based, North American focused chemical manufacturer and re-packager realized negative growth due to legacy CMO’s strategic decision to deprioritize contract manufacturing and focus more on direct sales to end markets.

APAC-based, > $15B market cap, global cell culture tools company focused on leveraging self-manufacturing footprint for higher-value proprietary media products and custom manufacturing for end customers.

US-based Cell Therapy company that is part of a global > $50B market cap biopharmaceutical company needed an external manufacturer who could make cGMP process liquids – cost effectively – in the small aliquots required for their current workflow process steps.